Skip to main content
Premium Trial:

Request an Annual Quote

Genomenon, Veritas Partner to Apply AI to Next Generation of Variant Classification

NEW YORK (GenomeWeb) – DNA sequencing company Veritas Genetics is partnering with genomic literature search engine Genomenon in an effort to move literature prioritization forward with the help of artificial intelligence.

The two companies said today that they would apply genomic language processing, machine learning, and AI to develop a new literature prioritization engine, following established variant classification schemes. Toward this goal, Veritas will integrate Genomenon's Mastermind analytic and data visualization tool into its own genome interpretation technology and advise Genomenon on enhancements to Mastermind.

In announcing the partnership, Ann Arbor, Michigan-based Genomenon called WGS interpretation the "single most critical hurdle to realize the promise of genomic medicine." Through this deal, the companies hope to drive down the cost and improve accuracy of variant classification while simplifying updates to classifications as the science advances.  

"Variant classification sits at the center of the genomic revolution," Genomenon CEO Mike Klein said in a statement. "We look forward to radically moving the field forward through our collective expertise and variant interpretation tools."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more